/

XNCR

Xencor, Inc.Open

23.61−1.43 −5.71%USD

NasdaqGM · as of Oct 13, 14:51 ET · 15m delay

Open

25.00

Prev close

25.04

Day range

23.5925.16

52-week range

10.3830.61

Volume

1.54M1.16×

Mkt cap

1.76B

P/E ttm

—

Fwd P/E

-6.64

EPS ttm

-2.16

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−22.87%

Price Chart

Yahoo Finance · delayed

XNCROct 13, 2026O 25.00H 25.16L 23.59C 23.61−1.43 (−5.71%)Vol 1.54M

SMA 5024.82
SMA 20016.19

1Y change +81.20% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

XNCR Xencor, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.08%
1 month: −3.28%
3 months: +57.93%
6 months: +88.73%
Year to date: +54.21%
1 year: +69.13%

Valuation & ownership

Market cap: 1.76B
Enterprise value: 1.58B
P/E (ttm): —
Forward P/E: -6.64
PEG ratio: —
Price / book: 3.49
Price / sales (ttm): 16.72
EV / EBITDA: -7.65
EPS (ttm): -2.16
EPS (forward): -3.56
Beta (5y monthly): 0.90
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 74.35M
Float: 54.25M
Short % of float: 31.23%
Short ratio (days): 11.27
Held by insiders: 1.22%
Held by institutions: 114.50%
Avg volume (3m): 1.33M
50-day average: 24.74
200-day average: 16.15
52-week change: +69.13%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 43.2
vs 50-day SMA: −4.89%
vs 200-day SMA: +45.83%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.55%
Realised vol (20d, ann.): 46.8%
From 52-week high: −22.87%
From 52-week low: +127.57%

ANR

Analyst Consensus

12 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

31.42

+33.07% implied

Low 20.00Median 30.00High 46.00

Recommendation trend

Now12 / 2 / 0
1m ago / 2 /

DES

About Xencor, Inc.

Yahoo Finance profile

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 260
Headquarters: Pasadena, CA, United States
Website: xencor.com

SEAS

Seasonality · XNCR

2013–2026 · monthly returns

Strongest month Nov +14.92%Weakest month Mar −5.15%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-21.0	5.6	-5.6	-1.1	-0.4	35.5	25.5	34.9	-8.5	-5.4			+54.2%
2025	-20.5	-16.0	-30.7	3.6	-27.4	-1.7	5.9	-2.3	44.3	25.4	17.7	-11.6	−33.4%
2024	-11.9	22.7	-3.6	-5.4	13.5	-20.3	7.9	-14.3	15.0	4.5	21.8	-10.2	+8.2%
2023	26.4	-2.4	-13.2	-5.2	2.5	-7.9	-2.7	-9.5	-8.3	-13.9	5.7	15.8	−18.5%
2022	-14.3	-8.9	-14.8	-6.4	-10.6	22.6	4.8	-8.0	-1.6	7.8	6.1	-12.4	−35.1%
2021	4.9	7.7	-12.6	-1.2	-9.6	-10.3	-10.8	10.0	-3.6	21.1	-8.4	10.8	−8.0%
2020	-1.3	-4.3	-8.0	-2.2	3.5	7.1	-7.1	18.8	8.5	-1.1	10.3	3.1	+26.9%
2019	-0.2	-16.0	2.4	-1.1	0.4	32.7	7.5	-15.3	-9.5	1.4	15.2	-12.7	−4.9%
2018	3.8	34.6	-2.1	-3.3	38.0	-7.5	0.6	12.3	-6.7	-16.0	28.4	-13.9	+65.0%
2017	-9.5	4.3	-3.7	7.3	-20.1	3.0	10.6	-7.4	6.0	-13.7	9.8	1.0	−16.7%
2016	-26.0	1.7	22.0	-8.7	15.3	34.4	-0.3	11.6	15.9	-13.1	20.1	3.0	+80.0%
2015	-5.5	3.0	-1.8	-7.2	27.6	21.1	1.9	-25.1	-27.1	-11.4	48.5	-9.1	−8.9%
2014	-3.8	27.9	4.4	-15.6	-11.1	32.0	-16.9	10.7	-12.9	15.9	3.9	43.1	+75.5%
2013													—

INSD

Insider Activity · XNCR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

82.4K shares

Sells, 6 months

30.4K shares

Net shares

+52K

Net change in insider shares

+6.10%

Date	Insider	Transaction	Shares	Value
Jun 17, 2026	Feigal Ellen G.Director	Sale at price 13.06 per share.	6.8K	$89.37K
Jun 15, 2026	Montgomery Alan BruceDirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Simpson Todd EDirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Ranieri Richard JDirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Gorman Kevin CharlesDirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Gustafson Kurt ADirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Klencke Barbara M.D.Director	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Feigal Ellen G.Director	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 15, 2026	Deshaies Raymond JosephDirector	Stock Award(Grant) at price 0.00 per share.	10.3K	—
Jun 14, 2026	Montgomery Alan BruceDirector	Sale at price 12.31 per share.	5.1K	$62.34K
Jun 14, 2026	Ranieri Richard JDirector	Sale at price 12.31 per share.	5.5K	$67.39K
Jun 14, 2026	Gorman Kevin CharlesDirector	Sale at price 12.31 per share.	7.5K	$92.66K
Jun 14, 2026	Gustafson Kurt ADirector	Sale at price 12.31 per share.	5.5K	$67.39K
Apr 9, 2026	Cornelissen Bart JanChief Financial Officer	Sale at price 12.29 per share.	3.5K	$42.99K
Mar 5, 2026	Desjarlais John ROfficer	Sale at price 11.02 - 11.25 per share.	6.6K	$73.88K
Mar 5, 2026	Dahiyat Bassil IshmaelChief Executive Officer	Sale at price 11.02 - 11.25 per share.	21.5K	$240.02K
Mar 5, 2026	Eckert Celia EGeneral Counsel	Sale at price 11.02 - 11.25 per share.	5K	$55.95K
Mar 4, 2026	Cornelissen Bart JanChief Financial Officer	Sale at price 11.25 per share.	2.5K	$28.30K
Mar 2, 2026	Desjarlais John ROfficer	Sale at price 11.90 per share.	2.7K	$31.68K
Mar 2, 2026	Dahiyat Bassil IshmaelChief Executive Officer	Sale at price 11.90 per share.	6.8K	$80.39K

XNCR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

XNCR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Xencor, Inc.

Seasonality · XNCR

Insider Activity · XNCR

Congress Trades · XNCR

Investors Holding XNCR

Investors Holding XNCR

Congress Trades · XNCR

Insider Activity · XNCR

Seasonality · XNCR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Xencor, Inc.

Financial Snapshot

Earnings & Dividends

News